Mice lacking TRPV1 develop significantly less oesophagitis after acid exposure compared with TRPV1+/+ mice [78], whilst administration of a TRPV1 antagonist before or after intracolonic TNBS administration significantly reduces colitis severity [79,80]. The gene discussed is TRPV1; the disease is esophagitis.